CARMAT (FR0010907956, ALCAR, PEA-PME eligible), designer and developer of the most advanced total artificial heart in the world, aimed at offering a therapeutic alternative to patients suffering from end-stage biventricular heart failure, today publishes its indicative financial schedule for the 2023 financial year.
This schedule may be subject to change. Publications will take place before the market opens.
To receive all of CARMAT’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.